Beryl Drugs

Who are in the management team of Beryl Drugs?

As of March 2023, the management team of Beryl Drugs includes Sanjay Sethi (Managing Director), Sudhir Sethi (Chairman), Abhinav Naik, and Shreya Saraf (both Independent Directors). Sanjay Sethi earns Rs. 21.0 lacs, while the other directors receive Rs. 40.0 k each, and Sudhir Sethi does not receive any remuneration.

As of March 2023, the management team of Beryl Drugs includes:<BR><BR>1. Sanjay Sethi - Executive Director / Managing Director / Promoter<BR>2. Sudhir Sethi - Chairman & Non-Executive Director<BR>3. Abhinav Naik - Independent Non-Executive Director<BR>4. Shreya Saraf - Independent Non-Executive Director<BR><BR>Sanjay Sethi is the only member with a specified remuneration of Rs. 21.0 lacs, while Sudhir Sethi does not receive any remuneration. Both Abhinav Naik and Shreya Saraf receive Rs. 40.0 k each.

Has Beryl Drugs declared dividend?

No Dividend History Available

Who are the peers of the Beryl Drugs?

Beryl Drugs' peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Ortin Global, Adline Chem Lab, Ganga Pharma, and Fabino Enter. Beryl Drugs has below-average management risk, growth, and capital structure compared to its peers, with a 1-year return of -38.52%.

Peers: The peers of Beryl Drugs are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Ortin Global, Adline Chem Lab, Ganga Pharma., and Fabino Enter.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Good management risk is found at Divi's Lab., Torrent Pharma, and the rest. Below Average management risk is noted at Ortin Global, Ganga Pharma., Fabino Enter, and Beryl Drugs. Growth is Excellent at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen at Divi's Lab., Torrent Pharma, Ortin Global, Ganga Pharma., Fabino Enter, and Beryl Drugs. Excellent capital structure is present at Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, while Good capital structure is found at Torrent Pharma, Average at Fabino Enter, and Below Average at Ortin Global, Adline Chem Lab, Ganga Pharma., and Beryl Drugs.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.69%, while Ortin Global has the lowest at -36.55%. Beryl Drugs' 1-year return of -38.52% is lower than both. Additionally, Ortin Global, Adline Chem Lab, Beryl Drugs, Ganga Pharma., and Fabino Enter all have negative six-month returns.

What is the technical trend for Beryl Drugs?

As of February 21, 2025, Beryl Drugs is in a bearish trend with moderate strength, indicated by bearish MACD, moving averages, and KST, alongside mildly bearish Bollinger Bands and Dow Theory signals.

As of 21 February 2025, the technical trend for Beryl Drugs has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this assessment include a bearish MACD on the weekly chart, bearish moving averages on the daily timeframe, and a bearish KST on the weekly. Additionally, Bollinger Bands are indicating a mildly bearish trend on both weekly and monthly charts. The Dow Theory shows a mildly bearish stance on the weekly but no trend on the monthly, further supporting the bearish outlook.

What does Beryl Drugs do?

Beryl Drugs Ltd manufactures, sells, and exports branded and generic pharmaceuticals, classified as a Micro Cap company with a market cap of INR 11 Cr. As of March 2025, it reported net sales of 40 Cr and a net profit of 2 Cr.

Overview:<BR>Beryl Drugs Ltd is engaged in the manufacture, sale, and export of branded and generic pharmaceutical formulations, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap company.<BR><BR>History:<BR>Beryl Drugs Ltd was incorporated on August 24, 1993, and acquired the running business of M/s Flora and Fauna Remedies Limited on December 15, 1993. The latest quarterly results reported net sales and profit for March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 40 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 2 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: INR 11 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 11.00<BR>- Industry P/E: 37<BR>- Dividend Yield: 0.00%<BR>- Debt-Equity: 0.34<BR>- Return on Equity: 6.11%<BR>- Price to Book: 1.13<BR><BR>Contact Details:<BR>Address: 133 Kanchan Bag, Indore Madhya Pradesh: 452001 <BR>Tel: 91-731-25076375/3046366 <BR>Email: beryldrugs25@yahoo.com <BR>Website: http://www.beryldurgs.com

Who are the top shareholders of the Beryl Drugs?

The top shareholders of Beryl Drugs include promoter Sanjay Sethi with 10.88% and public shareholder Samir Narendra Gupta with 4%. Individual investors collectively hold 68.69%, with no institutional holdings or pledged shares reported.

The top shareholders of Beryl Drugs include Sanjay Sethi, who is the promoter with the highest holding at 10.88%. The highest public shareholder is Samir Narendra Gupta, holding 4%. Additionally, individual investors collectively hold a significant portion of the company at 68.69%. There are no institutional holdings or pledged promoter shares reported.

How big is Beryl Drugs?

As of 24th July, Beryl Drugs Ltd has a market capitalization of 10.00 Cr, with recent net sales of 21.14 Cr and a net profit of 0.58 Cr. The balance sheet for March 2024 shows shareholder's funds of 8.92 Cr and total assets of 17.38 Cr.

As of 24th July, Beryl Drugs Ltd has a market capitalization of 10.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Beryl Drugs reported Net Sales of 21.14 Cr and a Net Profit of 0.58 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, showing Shareholder's Funds of 8.92 Cr and Total Assets of 17.38 Cr.

When is the next results date for Beryl Drugs?

Beryl Drugs will announce its results on 07 August 2025.

Beryl Drugs will declare its results on 07 August 2025.

Is Beryl Drugs overvalued or undervalued?

As of September 2, 2025, Beryl Drugs is considered very attractive with a PE ratio of 12.71 and an EV to EBITDA of 7.30, indicating it is undervalued compared to peers like Sun Pharma and Divi's Lab, despite a challenging year-to-date performance of -29.05%, as it has achieved a 3-year return of 168.59%, significantly outperforming the Sensex.

As of 2 September 2025, Beryl Drugs has moved from an attractive to a very attractive valuation grade. The company is currently undervalued, with a PE ratio of 12.71, an EV to EBITDA of 7.30, and a ROCE of 10.96%. In comparison, its peers exhibit significantly higher valuations, such as Sun Pharma with a PE ratio of 32.69 and Divi's Lab at 70.48, indicating that Beryl Drugs offers a more favorable investment opportunity relative to its competitors.<BR><BR>Despite a challenging year-to-date performance of -29.05%, Beryl Drugs has shown resilience with a 3-year return of 168.59%, significantly outperforming the Sensex's 36.32% return during the same period. This suggests that the market may not fully recognize the company's potential, further supporting the conclusion that it is undervalued.

How has been the historical performance of Beryl Drugs?

Beryl Drugs' historical performance shows fluctuating financial metrics, with net sales peaking at 26.89 Cr in Mar'23 but declining to 21.15 Cr by Mar'25, while total operating income also fell from 27.16 Cr to 22.56 Cr in the same period. Despite a decrease in profits and total assets, cash flow from operating activities improved to 2.00 Cr in Mar'25.

Answer:<BR>The historical performance of Beryl Drugs shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Beryl Drugs' net sales peaked at 26.89 Cr in Mar'23 but declined to 21.15 Cr by Mar'25. Other operating income increased from 0.00 Cr in Mar'19 to 1.41 Cr in Mar'25, contributing to a total operating income that reached a high of 27.16 Cr in Mar'23 before falling to 22.56 Cr in Mar'25. The raw material cost also saw a decline from 14.23 Cr in Mar'23 to 11.12 Cr in Mar'25, while total expenditure decreased from 24.95 Cr in Mar'23 to 19.91 Cr in Mar'25. Operating profit (PBDIT) slightly decreased from 2.68 Cr in Mar'24 to 2.65 Cr in Mar'25, with profit before tax showing a decline from 1.01 Cr in Mar'24 to 0.87 Cr in Mar'25. Profit after tax also decreased from 0.77 Cr in Mar'24 to 0.58 Cr in Mar'25. The company's total assets decreased from 17.39 Cr in Mar'23 to 15.95 Cr in Mar'25, while total liabilities also fell from 17.39 Cr to 15.95 Cr during the same period. Cash flow from operating activities improved to 2.00 Cr in Mar'25, contrasting with previous years where it was zero. Overall, Beryl Drugs has experienced both growth and decline in various financial aspects, reflecting a complex performance trajectory.

Are Beryl Drugs Ltd latest results good or bad?

Beryl Drugs Ltd's latest Q3 FY26 results are poor, showing a net loss of ₹0.17 crores compared to a profit last year, with revenue down 28.81% and a negative operating margin of -5.29%. The company's stock has also dropped 33.66% over the past year, indicating significant financial distress.

Beryl Drugs Ltd's latest results for Q3 FY26 indicate a troubling financial situation. The company reported a net loss of ₹0.17 crores, a significant decline from a profit of ₹0.05 crores in the same quarter last year. Revenue also fell sharply, down 28.81% year-on-year to ₹3.78 crores, marking a continued downward trend in sales.<BR><BR>The operating margin has turned negative at -5.29%, a stark contrast to the positive margin of 11.11% recorded in Q3 FY25. This suggests that the company is struggling to cover its fixed costs, indicating severe operational challenges. Additionally, Beryl Drugs has seen a significant decline in stock performance, with a 33.66% drop over the past year, further highlighting its struggles in the market.<BR><BR>Overall, the financial results reflect a company in distress, facing significant revenue erosion and operational inefficiencies. The outlook appears bleak unless there is a substantial turnaround in performance.

Should I buy, sell or hold Beryl Drugs Ltd?

Why is Beryl Drugs Ltd falling/rising?

As of 16-Mar, Beryl Drugs Ltd's stock price is rising to 20.69, up 2.43%, driven by short-term factors like sector outperformance. However, its long-term outlook is concerning due to significant operational losses and underperformance over the past year.

As of 16-Mar, Beryl Drugs Ltd's stock price is rising, currently at 20.69, reflecting an increase of 0.49 or 2.43%. This upward movement can be attributed to several factors. Firstly, the stock has outperformed its sector by 3.55% today, indicating a relative strength compared to its peers. Additionally, there has been a trend reversal as the stock has gained after two consecutive days of decline, suggesting a potential shift in market sentiment.<BR><BR>Despite the positive movement today, it is important to note that the stock has faced challenges over the longer term. Over the past year, it has generated a return of -16.23%, significantly underperforming the market, which has seen a return of 5.94%. Furthermore, the stock's performance over the last month shows a decline of -5.95%, and year-to-date, it is down -11.58%. <BR><BR>The stock's current valuation appears attractive with a return on capital employed (ROCE) of 11 and a low enterprise value to capital employed ratio of 1.1, indicating it is trading at a discount compared to its peers. However, the company has reported operating losses and weak long-term fundamental strength, with net sales declining by -20.14% over the past nine months and a poor EBIT to interest ratio of 0.75, which raises concerns about its ability to service debt.<BR><BR>In summary, while Beryl Drugs Ltd is experiencing a rise in stock price today due to short-term performance factors, the longer-term outlook remains challenging due to ongoing operational losses and underperformance relative to the market.

Which are the latest news on Beryl Drugs?